Retour aux projets

11487.1;4 PFLS-LS

Recombinant Immunoglobulins Applied for Autoimmune Medical Diagnostics

Résumé

Recombinant Immunoglobulins Applied for Autoimmune Medical Diagnostics

Textes supplémentaires

Abstract

This project addresses the commercial necessity for new recombinant antibodies to support a fast-growing product line related to anti-ganglioside and anti-MAG (myelin-associated glycoprotein) neuroimmunology autoantibody testing, diseases which potentially lead to general neurodegradation. In specific the generation of human recombinant antibodies and chimeric human-mouse IgG and IgM recombinant antibodies. Through gene-to-protein technologies in CHO-S and HEK293-S cell bioreactors and TGE (transient gene expression) we will achieve the R&D results carried out by the two university research partners, and combine the astute commercial expertise available from the industrial partner in auto-immune in vitro diagnostic kit development, to better serve the health care practitioner in this important field of disease diagnosis. These would represent the first uses of recombinant antibodies in any commercially available autoimmunity test.

Participants

Daniel Gygax

Kontaktperson

daniel.gygax@fhnw.ch

Fachhochschule Nordwestschweiz Daniel Gygax Gründenstrasse 40 Hochschule für Life Sciences 4132 Muttenz BL CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2010-05-31
Date de fin
2014-03-24
Coûts totaux approuvés
CHF 327088.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Nicht aufteilbare / nicht zuteilbare Forschung

Disciplines de recherche

  • T490 Biotechnology 100.0%